Tag: Penumbra

Overlook Medical Center participates in study evaluating best medical management for...

Overlook Medical Center’s Atlantic Neuroscience Institute is set to participate in the MIND trial: a prospective, multicentre, randomised controlled trial (RCT) examining the Artemis...
JET 7 XTRA FLEX

Penumbra introduces latest stroke thrombectomy aspiration technology at SNIS 2019

Penumbra announces commercial availability of the Penumbra JET 7 reperfusion catheter with XTRA FLEX technology, at the Society of NeuroInterventional Surgery (SNIS) 16th Annual...
perfusion weighted imaging

Perfusion-weighted parameter is “outstanding” at detecting penumbral flow in acute stroke

The performance of the best perfusion-weighted measure—time-to-maximum—to detect the upper penumbral flow threshold in ischaemic stroke has been deemed “outstanding” by the study investigators....

Penumbra announces acquisition of controlling interest in MVI health

Penumbra, a global healthcare company focused on innovative therapies, has announced it has closed on the acquisition of a controlling interest in its joint...

Penumbra launches JET 7 and Penumbra JET D in USA

Penumbra has announced US commercial availability of the Penumbra JET 7 and Penumbra JET D Reperfusion Catheters powered by the Penumbra ENGINE aspiration source....

COMPASS study finds ADAPT non-inferior to stent retriever for first-line mechanical...

The COMPASS study has found that the use of ADAPT as first-line mechanical thrombectomy therapy for acute ischaemic stroke results in non-inferior functional outcomes...

“Aspiration first” approach with Penumbra system demonstrates favourable outcomes for acute...

Penumbra announced results of the company-sponsored PROMISE study, demonstrating real-world safety and efficacy of the Penumbra system with ACE 68 and ACE64 reperfusion catheters...

3D revascularisation device “valuable adjunct” to ADAPT

According to one presentation given at the Society of NeuroInterventional Surgery’s 14th Annual Meeting (SNIS; 24–27 July, Colorado Springs, USA) the 3D revascularisation device...

Penumbra recalls 3D Revascularization device

According to a release issued by the US Food and Drug Administration (FDA) Penumbra has recalled its 3D Revascularization device due to a wire...

ASTER RCT finds no significant difference between ADAPT and stent retriever...

The primary results of the ASTER randomised controlled trial (RCT) have shown no statistically significant difference between ADAPT (a direct aspiration first pass technique)...

“Further improvement” in aspiration technology with ACE68

In 2016, Penumbra announced the launch of the ACE68 reperfusion catheter, part of the Penumbra System at the Society of NeuroInterventional Surgery 13th Annual...

Randomised trial of Penumbra 3D revascularisation device meets primary endpoints

The Penumbra 3D trial of the company’s 3D revascularisation device has successfully met the primary trial endpoints, demonstrating non-inferiority in both safety and efficacy...

Penumbra launches ACE 68 reperfusion catheter in USA

Penumbra has launched its new ACE 68 reperfusion catheter in the USA.  The catheter is part of the Penumbra System, and was launched at...

Long-term experience confirms ADAPT as effective treatment for stroke

A study of the long-term use of the ADAPT technique for the treatment of acute ischaemic stroke has confirmed that it is an efficient...

ADAPT to the Challenges of Stroke

Acute ischaemic stroke is the second most common cause of death and disability in Europe. The evidence in the recently published or presented randomised...

Penumbra Coil 400 safe and effective in small aneurysms

The results of a multicentre study have shown that catherisation with the larger profile coil delivery microcatheter and aneurysm occlusion with large volume coils...

Penumbra announces pricing of initial public offering

Penumbra has announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of...

ACE64 study demonstrates high revascularisation rates, quick procedure times

Penumbra has announced that the results of the European multicentre study of the company’s ACE64 thrombectomy system were presented in the Abstract Presentations Session at...

FDA clears Penumbra ACE64 for acute ischaemic stroke patients

Penumbra has announced that the company’s ACE64 aspiration thrombectomy system received 510(k) marketing clearance from the US Food and Drug Administration for the revascularisation...